Literature DB >> 12902210

Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats.

K Abo El Sooud1.   

Abstract

The pharmacokinetics of single intravenous and intramuscular administrations and milk antimicrobial equivalent activity of enrofloxacin at a dose of 5 mg per kilogram body weight were studied in clinically healthy lactating goats which were either not treated or had received 7.5 mg per kilogram body weight of albendazole orally. The concentrations of enrofloxacin in serum and milk were determined using microbiological assay. Following intravenous injection, enrofloxacin antimicrobial equivalent activity versus time data in serum was described by a two-compartmental open model. Albendazole treatment significantly decreased the elimination half-life (t(1/2beta)) (P>or=0.05) and the mean residence time (MRT) (P>or=0.05), whereas, the rate of enrofloxacin return to central compartment from peripheral tissue (K(21)) was significantly increased (P>or=0.01). In contrast, the volumes of distribution V(d(area)) and V(d(SS)) were significantly decreased (P>or=0.01 and P>or=0.05, respectively) in albendazole-treated goats. After intramuscular injection, enrofloxacin was rapidly absorbed in control and albendazole-treated lactating goats with absorption half-lives (t(1/2ab)) 0.43 and 0.39 h, respectively. The mean peaks of serum concentration (C(max)) were 0.68 and 0.65 mcg ml(-1) attained at (t(max)) 1.08 and 1.12 h, before and after albendazole dosing, respectively. The elimination half-life (t(1/2el)) and (MRT) following intramuscular injections were also shorter in the albendazole-treated lactating goats. The systemic bioavailability of enrofloxacin was significantly decreased from 110.16 to 84.38% in albendazole-treated lactating goats. Concomitant administration of albendazole with enrofloxacin resulted in significant alterations in the disposition kinetic of enrofloxacin and significant decrease in enrofloxacin concentrations in milk. Consequently, the interaction between albendazole and enrofloxacin could be of clinical significance and may require monitoring and adjustment of enrofloxacin dosage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902210     DOI: 10.1016/s1043-6618(03)00179-8

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats.

Authors:  Pedro Marín; Carlos M Cárceles; Elisa Escudero; Emilio Fernández-Varón
Journal:  Can J Vet Res       Date:  2007-01       Impact factor: 1.310

Review 2.  A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.

Authors:  Shane Ashley Pawluk; Craig Allan Roels; Kyle John Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 5.577

3.  The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs.

Authors:  Feray Altan; Duygu Neval Sayin Ipek; Orhan Corum; Simten Yesilmen Alp; Polat Ipek; Kamil Uney
Journal:  Trop Anim Health Prod       Date:  2019-06-23       Impact factor: 1.893

Review 4.  Antibacterial Drug Residues in Small Ruminant Edible Tissues and Milk: A Literature Review of Commonly Used Medications in Small Ruminants.

Authors:  Emily D Richards; Krysta L Martin; Catherine E Donnell; Maaike O Clapham; Lisa A Tell
Journal:  Animals (Basel)       Date:  2022-09-28       Impact factor: 3.231

Review 5.  The Applications of Gold Nanoparticle-Initialed Chemiluminescence in Biomedical Detection.

Authors:  Zezhong Liu; Furong Zhao; Shandian Gao; Junjun Shao; Huiyun Chang
Journal:  Nanoscale Res Lett       Date:  2016-10-18       Impact factor: 4.703

6.  Pharmacokinetics and tissue residue of enrofloxacin in healthy, Eimeria-infected broiler chickens and those pre-treated with amprolium and toltrazuril.

Authors:  M Atef; H A El-Banna; H Y Elzorba; A M Soliman
Journal:  Int J Vet Sci Med       Date:  2020-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.